Ceruloplasmin oxidation, a feature of parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention

Journal of Neuroscience

Volumn 31, Issue 50, 2011, Pages 18568-18577

  Olivieri, Stefano ^a   Conti, Antonio ^a   Iannaccone, Sandro ^a   Cannistraci, Carlo V ^a,d   Campanella, Alessandro ^b,f   Barbariga, Marco ^a   Codazzi, Franca ^a   Pelizzoni, Ilaria ^a   Magnani, Giuseppe ^a   Pesca, Mariasabina ^a,e   Franciotta, Diego ^c   Cappa, Stefano F ^a,f   Alessio, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^e UNIVERSITY OF SALERNO   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; IRON;

ACIDITY; ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OXIDATION; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CARBONYLATION; RAT; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANIMALS; ASTROCYTES; CELLS, CULTURED; CERULOPLASMIN; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 83455177604     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3768-11.2011     Document Type: Article

References (52)

1. Baraj B, Cortina JL, Sastre A, Granados M (1998) Copper interference on spectrophotometric determination of iron and their simultaneous determination using bathophenantroline-disulfonic acid disodium salt. Fresenius J Anal Chem 360:263-265.
2. Bettegazzi B, Mihailovich M, Di Cesare A, Consonni A, Macco R, Pelizzoni I, Codazzi F, Grohovaz F, Zacchetti D (2011) beta-Secretase activity in rat astrocytes: translational block of BACE1 and modulation of BACE2 expression. Eur J Neurosci 33:236-243.
3. Bharucha KJ, Friedman JK, Vincent AS, Ross ED (2008) Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 255:1957-1962.
4. Boll MC, Sotelo J, Otero E, Alcaraz-Zubeldia M, Rios C (1999) Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett 265:155-158.
5. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33:1717-1723.
6. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R (2010) Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen 25:490-497.
7. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 124 [Suppl]:96-107.
8. Cannistraci CV, Montevecchi FM, Alessio M (2009) Median-modified Wiener filter provides efficient denoising, preserving spot edge and morphology in 2-DE image processing. Proteomics 9:4908-4919.
9. Cannistraci CV, Ravasi T, Montevecchi FM, Ideker T, Alessio M (2010) Non-linear dimension reduction and clustering by minimun curvilinearity unfold neuropathic pain and tissue embryological classes. Bioinformatics 26:i531-i539.
10. Carrí MT, Ferri A, Cozzolino M, Calabrese L, Rotilio G (2003) Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 61:365-374.
11. Choi SY, Kwon HY, Kwon OB, Eum WS, Kang JH (2000) Fragmentation of human ceruloplasmin induced by hydrogen peroxide. Biochimie 82:175-180.
12. Codazzi F, Di Cesare A, Chiulli N, Albanese A, Meyer T, Zacchetti D, Grohovaz F (2006) Synergistic control of protein kinase Cγ activity by ionotropic and metabotropic glutamate receptor inputs in hippocampal neurons. J Neurosci 26:3404-3411.
13. Conti A, Ricchiuto P, Iannaccone S, Sferrazza B, Cattaneo A, Bachi A, Reggiani A, Beltramo M, Alessio M (2005) Pigment epithelium-derived factor is differentially expressed in peripheral neuropathies. Proteomics 5:4558-4567.
14. Conti A, Iannaccone S, Sferrazza B, De Monte L, Cappa S, Franciotta D, Olivieri S, Alessio M (2008) Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Proteomics Clin Appl 2:1628-1637.
15. Cozzi A, Rovelli E, Frizzale G, Campanella A, Amendola M, Arosio P, Levi S (2010) Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis 37:77-85.
16. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A (2003) Protein carbonylation in human diseases. Trends Mol Med 9:169-176.
17. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822.
18. De Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, Kaplan J (2007) Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 26:2823-2831.
19. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, et al. (2010) Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142:857-867.
20. Fahn S (1987) Systemic therapy of dystonia. Can J Neurol Sci 14:528-532.
21. Götz ME, Double K, Gerlach M, Youdim MB, Riederer P (2004) The relevance of iron in the pathogenesis of Parkinson's disease. AnnN Y Acad Sci 1012:193-208.
22. Grimm S, Hoehn A, Davies KJ, Grune T (2011) Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res 45:73-88.
23. Harris ZL, Klomp LW, Gitlin JD (1998) Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 67:972S-977S.
24. Hellman NE, Gitlin JD (2002) Ceruloplasmin metabolism and function. Annu Rev Nutr 22:439-458.
25. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427-442.
26. Italian Neurological Society (2003) The diagnosis of Parkinson's disease. Neurol Sci 24 [Suppl 3]:S157-S164.
27. Jeong SY, David S (2003) Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 278:27144-27148.
28. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C (2011) Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134:50-58.
29. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH (2001) Oxidative modification of human ceruloplasmin by peroxyl radicals. Biochim Biophys Acta 1568:30-36.
30. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH, Kang TC (2002) Carnosine and related dipeptides protect human ceruloplasmin against peroxyl radical-mediated modification. Mol Cells 13:498-502.
31. Kohane IS, Kho AT, Butte AJ (2003) Microarrays for an integrative genomics. Cambridge, MA: MIT.
32. Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet MF, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, Jenner P, Melamed E, Myers RH, Parker D Jr, Price DL (2007a) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 66:251-257.
33. Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E (2007b) The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol 66:329-336.
34. Loeffler DA, DeMaggio AJ, Juneau PL, Brickman CM, Mashour GA, Finkelman JH, Pomara N, LeWitt PA (1994) Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord 8:190-197.
35. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932-942.
36. Madsen E, Gitlin JD (2007) Copper and iron disorders of the brain. Annu Rev Neurosci 30:317-337.
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
38. Merle U, Tuma S, Herrmann T, Muntean V, Volkmann M, Gehrke SG, Stremmel W (2010) Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. J Gastroenterol Hepatol 25:1144-1150.
39. Mittal B, Doroudchi MM, Jeong SY, Patel BN, David S (2003) Expression of a membrane-bound form of the ferroxidase ceruloplasmin by leptomeningeal cells. Glia 41:337-346.
40. Moos T, Rosengren Nielsen T, Skjørringe T, Morgan EH (2007) Iron trafficking inside the brain. J Neurochem 103:1730-1740.
41. Muller T, Hefter H, Hueber R, Jost WH, Leenders KL, Odin P, Schwarz J (2004) Is levodopa toxic? J Neurol 251 [Suppl 6]:VI/44-46.
42. Musci G, Bonaccorsi di Patti MC, Fagiolo U, Calabrese L (1993) Age-related changes in human ceruloplasmin. Evidence for oxidative modifications. J Biol Chem 268:13388-13395.
43. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM (2007) Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68:1820-1825.
44. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S (2002) Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 22:6578-6586.
45. Pelizzoni I, Macco R, Morini MF, Zacchetti D, Grohovaz F, Codazzi F (2011) Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell 10:172-183.
46. Rathore KI, Kerr BJ, Redensek A, López-Vales R, Jeong SY, Ponka P, David S (2008) Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage. J Neurosci 28:12736-12747.
47. Ruggeri G, Santambrogio P, Bonfiglio F, Levi S, Bugari G, Verardi R, Cazzola M, Invernizzi R, Zambelli LM, Albertini A (1992) Antibodies for denatured human H-ferritin stain only reticuloendothelial cells within the bone marrow. Br J Haematol 81:118-124.
48. Tapryal N, Mukhopadhyay C, Das D, Fox PL, Mukhopadhyay CK (2009) Reactive oxygen species regulate ceruloplasmin by a novel mRNA decay mechanism involving its 3-untranslated region: implications in neurodegenerative diseases. J Biol Chem 284:1873-1883.
49. Texel SJ, Xu X, Harris ZL (2008) Ceruloplasmin in neurodegenerative diseases. Biochem Soc Trans 36:1277-1281.
50. Tórsdóttir G, Sveinbjörnsdóttir S, Kristinsson J, Snaedal J, Jóhannesson T (2006) Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study. J Neurol Sci 241:53-58.
51. Vassiliev V, Harris ZL, Zatta P (2005) Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 49:633-640.
52. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306-325.